TACRINE DONEPEZIL

Tacrine This page contains recent news articles, when available, and an overview of Tacrine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns. Tacrine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Tacrine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. For the treatment of mild to moderate dementia of the Alzheimer's typeInteractions for Tacrine: Drug-Drug Interactions Possible metabolic basis for interactions: Tacrine is primarily eliminated by hepatic metabolism via cytochrome P450 drug metabolizing enzymes. Drug-drug interactions may occur when Cognex is given concurrently with agents such as theophylline that undergo extensive metabolism via cytochrome P450 IA2. Theophylline. Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold. Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently. The effect of theophylline on tacrine pharmacokinetics has not been assessed. Cimetidine. Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively. Anticholinergics. Because of its mechanism of action, Cognex has the potential to interfere with the activity of anticholinergic medications.